Brachytherapy or Conformal External Radiotherapy for Prostate Cancer: A Single-Institution Matched-Pair Analysis

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 1, 2010, Pages 43-49

  Pickles, Tom ^a   Keyes, Mira ^a   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Brachytherapy; Conformal radiation; Outcomes; Prostate cancer; Toxicity

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL CONTROL; BRACHYTHERAPY; CURE RATE; DOSE ESCALATION; EXTERNAL BEAM RADIATION THERAPY; EXTERNAL RADIOTHERAPY; GLEASON SCORES; LOCALIZED PROSTATE CANCER; MATCHED-PAIR DESIGN; OUTCOMES; PERFECT MATCHES; POST TREATMENT; PROGNOSTIC VARIABLES; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; SECONDARY USE; TRACK RECORD; TREATMENT FAILURE;

FLUORINE CONTAINING POLYMERS; ONCOLOGY; PATIENT MONITORING; PEELING; TOXICITY;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; REFERENCE VALUES;

EID: 72049118716     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.081     Document Type: Article

References (30)

1. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
2. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
3. Eade T.N., Horwitz E.M., Ruth K., et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 71 (2008) 338-345
4. Zelefsky M., Yamada Y., Hunt M., et al. Comparison of 7-year outcomes between LDR brachytherapy and high dose IMRT for patients with clinically localized prostate cancer. ASTRO Annual Scientific Meeting. Vol. 69. Los Angeles, CA. Int J Radiat Oncol Biol Phys (2007)
5. Morris W., Keyes M., Palma D., et al. Evaluation of dosimetric parameters and disease response in 1006 consecutive patients treated with 125-Iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 1432-1438
6. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
7. Keyes M., Pickles T., Agranovich A., et al. 125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys 60 (2004) 40-50
8. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
9. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
10. Williams S.G., Pickles T., Kestin L., et al. A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems. Int J Radiat Oncol Biol Phys 65 (2006) 1494-1500
11. Bates A.T., Pickles T., and Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 148-153
12. Keyes M., Miller S., Morovan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy. Sequential outcomes of 712 men. Int J Radiat Oncol Biol Phys 73 (2009) 1023-1032
13. Cheung P.C., Loblaw D.A., Pickles T., et al. Timing of androgen deprivation therapy after radical radiotherapy failure: A survey of Canadian practitioners. Radiother Oncol 80 (2006) S66-S66
14. Morris W., Keyes M., Palma D., et al. Population based study of biochemical and survival outcomes after permanent (125)I brachytherapy for low- and intermediate-risk prostate cancer. Urology 73 (2009) 860-867
15. Pickett B., Ten Haken R.K., Kurhanewicz J., et al. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 59 (2004) 665-673
16. Crook J.M., Bahadur Y.A., Bociek R.G., et al. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79 (1997) 328-336
17. Stock R.G., Klein T.J., Cesaretti J.A., et al. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 74 (2009) 753-758
18. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567-4573
19. Arlen P.M., Bianco F., Dahut W.L., et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179 (2008) 2181-2185 discussion 2185-2186
20. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
21. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033
22. Zietman A.L. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 299 (2008) 898-899
23. Zietman A.L. The Titanic and the iceberg: prostate proton therapy and health care economics. J Clin Oncol 25 (2007) 3565-3566
24. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91-98
25. Macdonald A.G., Keyes M., Kruk A., et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 63 (2005) 155-163
26. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825-834
27. Liu M., Pickles T., Agranovich A., et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 59-67
28. Liu M., Pickles T., Berthelet E., et al. Urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiother Oncol 74 (2005) 197-201
29. Peters L.J., Withers H.R., and Brown B.W. Complicating issues in complication reporting. Int J Radiat Oncol Biol Phys 31 (1995) 1349-1351
30. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 373 (2009) 301-308